Nontypeable Haemophilus influenzae is a common cause of respiratory tract disease and initiates infection by colonizing the nasopharynx. The H. influenzae Hap adhesin is an autotransporter protein that was discovered because it promotes intimate interaction with human epithelial cells. Hap contains an extracellular domain called Hap s that has adhesive and protease activity and an outer membrane domain called Hap b that serves to present Hap s on the surface of the cell. Hap s purified from nontypeable H. influenzae strain P860295 was used to immunize BALB/c mice intranasally. Immunization stimulated significant mucosal and serum anti-Hap s antibody titers, which were augmented by the addition of mutant cholera toxin (CT-E29H) as an adjuvant. Immunization was associated with a marked reduction in the density of nasopharyngeal colonization when mice were challenged with a heterologous strain of nontypeable H. influenzae. These results suggest that intranasal immunization with Hap formulated with CT-E29H may be a valuable vaccine strategy for the prevention of nontypeable H. influenzae disease.
Hap belongs to the autotransporter family of proteins and is synthesized as a precursor protein with 3 functional domains, including an N-terminal signal sequence, an internal 110-kDa domain called Hap s , and a C-terminal 45-kDa domain called Hap b [5] [6] [7] . The signal sequence directs export out of the cytoplasm and into the periplasm. Hap b , in turn, inserts into the outer membrane and facilitates presentation of Hap s on the surface of the organism [7] . Hap s harbors the adhesive activity responsible for bacterial interaction with epithelial cells and for bacterial aggregation [4] . In addition, Hap s has serine protease activity and mediates autoproteolytic cleavage, which results in the separation of itself from Hap b and release into the extracellular space [7] . Hap s accumulates on the bacterial surface in the presence of secretory leukocyte protease inhibitor, a natural component of respiratory secretions that blocks Hap autoproteolysis [4] .
Current vaccines against H. influenzae are based on the serotype b capsular polysaccharide and do not protect against NTHi strains. Efforts to develop a vaccine effective against NTHi have been hindered by the considerable genetic and antigenic heterogeneity among these strains [8] . As an example, the NTHi P1 and P2 outer membrane proteins elicit antibodies that are bactericidal in vitro and protective in animal models but only against the homologous strain [9] [10] [11] . Several conserved outer membrane proteins have been identified as candidate vaccine antigens, but these proteins are minor components of the cell wall and have unknown functions [12] [13] [14] [15] . Because of the fundamental role of colonization in the pathogenesis of NTHi disease, bacterial molecules that mediate adherence to host epithelium are logical vaccine antigens.
In the present study, we examined Hap as a potential vaccine antigen against NTHi. Using the mouse nasopharyngeal colonization model, we found that intranasal immunization with purified Hap s stimulated significant antibody titers against Hap s and resulted in protection against colonization with a heterologous strain.
Materials and Methods

Bacterial strains and plasmids.
NTHi strains N187 and P860295 were isolated from the middle ear fluid of children with acute otitis media, whereas NTHi strain TN106 was isolated from a patient with pneumonia [5, 16] . Strain N187 is the strain from which the hap gene was originally cloned. Strain P860295 was obtained from Charles Brinton (University of Pittsburgh), and strain TN106 was obtained from Eric Hansen (University of Texas, Southwestern School of Medicine). Strain TN106.P2 is a derivative of TN106 that was recovered after plating on medium that contained 100 mg/mL of streptomycin, then inoculating into the nasopharynx of a BALB/c mouse. Strain TN106.P2hap is a Hap-deficient derivative of TN106.P2 that contains a kanamycin cassette in the hap gene and was generated as described elsewhere [17] . Strains TN106, TN106.P2, and TN106.P2hap are indistinguishable in terms of morphology and growth characteristics. H. influenzae strain DB117 is a rec1 mutant of Rd, a capsule-deficient serotype d strain [18] . DB117 contains a nonfunctional hap gene because of a spontaneous nonsense mutation at codon 710 and is nonadherent in assays with cultured epithelial cells [19] . Escherichia coli strain DH5a is a laboratory strain that has been described elsewhere [20] .
The plasmids pGJB103 and pUC19 are cloning vectors, which have been described elsewhere [20, 21] . pJS106 is a derivative of pGJB103 and encodes wild-type Hap from strain N187 [5] .
Culture and storage conditions. H. influenzae strains were grown on chocolate agar supplemented with 1% IsoVitaleX, on brain-heart infusion agar supplemented with hemin and nicotinamide adenine dinucleotide (NAD; BHI-XV agar), or in brainheart infusion broth supplemented with hemin and NAD (BHIs), as described elsewhere [22] . These strains were stored at Ϫ80ЊC in BHI broth with 20% glycerol. E. coli strains were grown on LuriaBertani (LB) agar or in LB broth and were stored at Ϫ80ЊC in LB broth with 50% glycerol. Antibiotic concentrations used to select for plasmids included 5 mg/mL of tetracycline in H. influenzae and 100 mg/mL of ampicillin and 12.5 mg/mL of tetracycline in E. coli.
Recombinant DNA methods. DNA ligations, restriction endonuclease digestions, and gel electrophoresis were performed, according to standard techniques [20] . Plasmids were introduced into E. coli by electroporation [23] . In H. influenzae, transformation was performed according to the MIV method of Herriott et al. [24] .
Cloning and sequencing of hap from strains P860295 and TN106. The hap gene was cloned from strains P860295 and TN106 using polymerase chain reaction (PCR) and primers corresponding to sequence flanking hap in strain N187. Reactions were performed with Expand polymerase (Roche Molecular Biochemicals), to enhance long-range amplification and to minimize PCRrelated errors. The 5 primer was based on sequence beginning ∼500 bp upstream of hap (5 -TGCAGGATCCCCGCAGACTGGATT-GTTG-3 ), and the 3 primer corresponded to sequence beginning ∼50 bp downstream of hap (5 -TGCAGGATCCGATCTGCCCC-ACCTTGTT-3 ). To facilitate initial cloning, both the 5 and 3 primers included a BamHI site. The amplified genes were cloned initially into BamHI-digested pUC19. Subsequently, they were excised from pUC19 and were cloned into BglII-digested pGJB103.
Nucleotide sequencing was performed by using an Applied Biosystems automated sequencer and the Big Dye Terminator Premix-20 kit (Applied Biosystems/Perkins Elmer). Double-stranded plasmid DNA was used as template, and sequencing was carried out along both strands. With strain TN106, clones from 2 separate PCR assays were sequenced, and the 2 sequences were identical. With strain P860295, a single clone was sequenced. The sequences for hap P860295 and hap TN106 have been submitted to GenBank, and the accession numbers are AF369379 and AF369380, respectively.
Protein analysis and Western immunoblotting. Outer membrane proteins were isolated from H. influenzae on the basis of sarcosyl insolubility, as described elsewhere [25] . Proteins released into the culture supernatant were precipitated by using trichloroacetic acid, as described elsewhere [5] . Proteins were resolved by SDS-PAGE on 7%-10% polyacrylamide gels, and Western blots were performed as detailed elsewhere [26, 27] . Hap was detected by using guinea pig antiserum GP74, which was raised against purified Haps and reacts with full-length Hap and Haps. Antiserum GP74 is specific for Hap and demonstrates no reactivity with outer membrane proteins, extracellular proteins, or surface-associated proteins in strain DB117.
Adherence assays.
Adherence assays were performed with Chang conjunctival epithelial cells (Wong-Kilbourne derivative, clone 1-5c-4 [human conjunctiva]), as described elsewhere [28] . The percentage of adherence was calculated by dividing the number of adherent colony-forming units per monolayer by the number of inoculated colony-forming units. To examine whether guinea pig antiserum GP74 was capable of blocking adherence, bacteria were preincubated with a 1:100 or 1:500 dilution of heat-inactivated antiserum for 30 min and then were inoculated onto epithelial monolayers. In pilot experiments, antiserum GP74 had no effect on bacterial viability or bacterial aggregation.
Purification of Hap s protein from strain P860295. To purify Hap s from strain P860295, bacteria were grown in BHI broth for 18 h at 35ЊC with aeration. The bacterial cells were pelleted by centrifuging at 10,000 g at 4ЊC and then discarded. The supernatant was concentrated 20-fold by use of an Amicon stirred cell, then adjusted to 60% saturation with ammonium sulfate powder, incubated overnight at 4ЊC, and centrifuged at 17,000 g for 1 h at 4ЊC. The resulting precipitate was dissolved in 50 mM sodium phosphate buffer (pH 5.8), 1 mM EDTA, and 50 mM NaCl and was dialyzed at 4ЊC against the same buffer (buffer 1), then centrifuged at 100,000 g for 1 h at 4ЊC to remove insoluble material. A 10-mL bed volume CM sepharose (Pharmacia) column was equilibrated with buffer 1, and 70 mL of the above soluble material was loaded onto the column at a flow rate of 5 mL/min. The column was washed with buffer 1 until the optical density at 280 nm (OD 280 ) reached baseline, and the flow-through material was discarded. Next the column was washed with 3 column volumes of 50 mM sodium phosphate buffer (pH 7.0), 1 mM EDTA, and 50 mM NaCl. Hap s was eluted with 50 mM sodium phosphate buffer (pH 8.0), 1 mM EDTA, and 0.5 mM NaCl. Fractions were examined by SDS-PAGE, and fractions that contained Hap s were pooled.
Determination of N-terminal amino-acid sequence. To confirm Signal sequence, histidine, aspartic acid, and serine residues at the active site and P1, P3, and P4 residues at primary cleavage site are absolutely conserved among all 3 proteins.
the identity of purified Hap s , protein was resolved by SDS-PAGE and then electrotransferred to a polyvinylidene membrane. After staining with Coomassie brilliant blue R-250, protein was excised from the membrane and was submitted to Midwest Analytical. Amino terminal sequence determination was performed by means of automated Edman degradation, using a Perkin Elmer Biosystems model 477A sequencing system. Intranasal immunization of mice. Groups of 10 6-week-old, female BALB/c mice were immunized intranasally with Hap s purified from strain P860295. Hap s was diluted in Dulbecco's PBS (D-PBS) to a final concentration of 5 or 15 mg/40 mL, with or without 0.1 mg CT-E29H (a mutant cholera toxin used as an adjuvant) [29] . Control mice received D-PBS alone or D-PBS with 0.1 mg CT-E29H, again in 40-mL volumes.
Before intranasal immunization, mice were anesthetized with an injectable anesthetic mixture of ketamine (0.008 body mL ϫ grams weight) / xylazene (0.007 body weight), a mixture that mL ϫ grams maintains a state of anesthesia for 15-20 min. Immunizing preparations were delivered by pipette in a volume of 20 mL/nostril. The pipette was positioned so that the tip touched the opening of the nostril and the liquid was drawn into the nasopharynx during breathing. Immediately after immunization, mice were placed in a supine position for 3-5 min. Mice were immunized at weeks 0, 1, 3, and 5.
Collection of bronchoalveolar and nasal washes. To collect mucosal washes for measurement of antibodies, mice were killed by cervical dislocation. In preparation for bronchoalveolar lavage (BAL), animals were pinned to a block, exposing the anterior surface of the neck. The skin and connective tissue were removed above the trachea, and a 22-gauge butterfly needle with 3.5-inch tubing (Abbott Laboratories) was introduced into the trachea just below the larynx. The needle was attached to a 1-mL tuberculin syringe (Becton Dickinson) that contained 1.0 mL of RPMI 1640 medium, which was gently pushed into the lungs and then aspirated 5 times. After the fifth aspiration, lavage fluid was transferred to a microfuge tube that contained 50 mL heat-inactivated fetal bovine serum and then was centrifuged for 7 min at 16,110 g to remove cells. In preparation for nasal washes (NWs), the needle and syringe were washed and refilled with 0.5 mL of RPMI. Subsequently, the needle was placed just inside the opening of the nostril, and fluid was pushed gently into the nasal cavity and then was collected in a microfuge tube that contained 25 mL heat-inactivated fetal bovine serum. Samples were frozen at Ϫ20ЊC until testing.
Measurement of mucosal and serum antibody responses by ELISA. Before measuring antibodies, samples of BAL fluid, NW fluid, or serum from a given group of mice were pooled. To quantitate antibody responses against Hap s , purified Hap s was diluted in PBS to a concentration of 5 mg/mL, and 50-mL volumes were added to wells of Maxisorp 96-well ELISA plates (Nunc). Plates were incubated at 37ЊC for 90 min, cooled to room temperature, washed once with PBS/0.1% Tween 20 (washing buffer), and then were blocked with 1% bovine serum albumin (BSA)/PBS at 37ЊC for 2 h. Mouse mucosal washes and serum samples were diluted in 1% BSA/PBS/0.05% Tween 20 (diluent buffer) and were transferred to coated and blocked plates. After incubation at 37ЊC overnight, plates were washed and then were incubated with a 1:15,000 dilution of biotinylated rabbit anti-mouse IgG or mouse IgA at 37ЊC for 2 h. Next, plates were washed again and then were incubated with a 1:10,000 dilution of streptavidin-horseradish peroxidase (Zymed) at room temperature for 30 min. Finally, plates were washed and incubated with ABTS peroxidase substrate (Kirkegaard and Perry Laboratories) at room temperature for 20 min. Reactions were stopped with 1% SDS, and absorbance of ABTS was measured at 405 nm. ELISA end points were defined as the highest dilution of sample giving an . Intranasal challenge of mice. Two weeks after the final immunization, animals were challenged intranasally with 6 ∼ 1 ϫ 10 cfu of strain TN106.P2. The TN106.P2 challenge strain was prepared for challenge by first inoculating 3 chocolate agar plates from frozen stocks. Plates were incubated overnight at 37ЊC in 5% CO 2 . Five milliliters of D-PBS was added to each plate, and the bacteria were resuspended with a bent glass rod. Bacteria from all 3 plates were combined with an additional 15 mL of D-PBS, and the suspension was poured over a D-PBS prewetted nylon wool column, to remove clumps of bacteria and debris. The suspension was diluted with D-PBS to an OD 490 of 0.33, which was shown to equal cfu/mL. This suspension was used for challenge. Mice 8 ∼ 1.0 ϫ 10 were anesthetized, as described for immunization, and 5 mL of bacteria were administered in each nostril. Twenty minutes after the challenge began, an aliquot of the bacterial suspension was diluted in D-PBS and was plated onto BHI-XV agar to determine the actual inoculum. Three days after challenge, animals were killed, and nasal tissue was harvested, weighed, homogenized, and plated on BHI-XV plates that contained 100 mg/mL of streptomycin. After incubation of plates overnight, colonies were counted, and the colony-forming units per grams of nasal tissue were determined. The variability of the standard errors of the means between the groups in the present study violates the assumption of equal variance between groups, making it more appropriate to first rank the data and then use an analysis of variance. Accordingly, statistical differences among groups were analyzed by use of the Tukey-Kramer test, a nonparametric method applied when data points are not normally distributed [30, 31] .
Results
Cloning and sequencing of the hap genes from strains TN106 and P860295. In earlier work, we cloned and sequenced the hap gene from NTHi strain N187. In the current study, we ∼ 2 ϫ 10 mean ‫ע‬ SE surements made in triplicate from a representative experiment. To examine inhibitory effect of guinea pig antiserum GP74, bacteria were preincubated with a 1:100 or 1:500 dilution of antiserum for 30 min and then were inoculated onto epithelial monolayers. In these experiments, adherence by DB117/pGJB103 (vector) was 3%-5%.
cloned and sequenced the hap gene from strains P860295 and TN106. The hap TN106 gene encodes a protein with 1392 amino acids, and the hap P860295 gene encodes a slightly larger protein with a total of 1436 amino acids. Hap TN106 is 80% similar and 77% identical to Hap N187 , whereas Hap P860295 is 85% similar and 83% identical to Hap N187 . Overall, the predicted amino acid sequences of Hap TN106 and Hap P860295 are 82% similar and 79% identical to each other.
As shown schematically in figure 1 , alignment of the amino acid sequences of Hap TN106 , Hap P860295 , and Hap N187 revealed absolute identity through the first 47 amino acids, then significant divergence over the next 330-335 amino acids, and then marked similarity over the final 1000-1050 amino acids, including the C-terminal two-thirds of the Hap s domain and the entire Hap b domain. The signal peptide and the catalytic triad (His, Asp, and Ser) are completely conserved in all 3 proteins. Similarly, the amino acids in the P1 (leucine), P3 (serine), and P4 (glutamine) positions of the primary cleavage site between Hap s and Hap b are invariant.
Functional comparison of Hap from heterologous strains. To examine the function of the Hap proteins expressed by strains TN106 and P860295, hap TN106 and hap P860295 were cloned into pGJB103 and then were introduced into H. influenzae strain DB117, a nonadherent laboratory strain. As shown in figure 2 , Western analysis of outer membrane proteins and secreted proteins from strain DB117/pHap(TN106) revealed a full-length protein at ∼155 kDa and Hap s at ∼110 kDa that was virtually identical to control samples from strain DB117/pJS106 (Hap N187 ). Examination of protein samples from strain DB117/pHap (P860295) revealed that full-length Hap migrated at ∼160 kDa and that Hap s migrated as 2 bands at ∼115 and ∼110 kDa, presumably reflecting autoproteolysis at 2 sites [32] .
To assess adhesive activity, DB117/pHap(TN106) and DB117/ pHap(P860295) were compared with DB117/pJS106 (Hap N187 ) in adherence assays with Chang conjunctival epithelial cells. As shown in figure 3 , both Hap TN106 and Hap P860295 promoted appreciable levels of adherence to these cells, similar to levels associated with Hap N187 . To extend this result, we examined whether antiserum raised against Hap s purified from strain N187 could block adherence mediated by either Hap P860295 or Hap TN106 . As shown in figure 3 , in experiments with DB117/pHap(TN106), preincubation with a 1:500 dilution of guinea pig antiserum GP74 resulted in a nearly 50% decrease in adherence, and preincubation with a 1:100 dilution of GP74 resulted in a 70% decrease in adherence. Similarly, with DB117/pHap(P860295), a 1:500 dilution of GP74 blocked adherence by 40%, and a 1:100 dilution of GP74 blocked adherence by almost 80%. As a control, we examined preimmune guinea pig serum, which had no inhibitory effect on Hap-mediated adherence ( figure 3) . Purification of native Haps. To purify Hap s , we exploited the fact that Hap autoproteolysis results in extracellular release of Hap s . In particular, we incubated strain P860295 to stationary phase, then removed organisms by centrifugation and recovered the culture supernatant. Protein was precipitated from the culture supernatant with ammonium sulfate and was subjected to ionexchange chromatography. Using this purification scheme, we recovered a predominance of a 110-kDa protein and a small amount of a 105-kDa protein (figure 4), both of which reacted NOTE. Four groups of 10 animals were immunized at weeks 0, 1, 3, and 5, and mucosal samples were collected at week 6 in 5 animals from each group and week 7 in the other 5 animals from each group. Samples from each group were pooled, and IgA and IgG levels were measured by ELISA. BAL, bronchoalveolar lavage; NW, nasal wash.
with guinea pig antiserum GP74 against Hap s (not shown). Amino-terminal amino-acid sequencing was performed on the 110-kDa band and revealed the sequence GHTYFGI, confirming the identity as Hap s . The 105-kDa band is likely another product of autoproteolysis.
Mucosal and serum antibody responses. In general, intranasal immunization stimulates primarily a secretory immune response [33] . The addition of CT-E29H to the immunizing material augments the secretory immune response and helps to induce a serum antibody response as well [29] . The volume of immunizing material used in our studies (40 mL) probably resulted in some of the material being aspirated into the lungs, thus further increasing the immune response in the serum. Table  1 shows the anti-Hap s IgA and IgG titers measured in pooled BAL and NW fluid from mice immunized with 15 mg of native Hap s purified from strain P860295. Titers of IgA exceeded titers of IgG, especially in NWs and especially at 2 weeks after the final immunization (week 7). Titers of both IgA and IgG were augmented by the addition of CT-E29H. Table 2 shows the anti-Hap s IgG titers measured in serum from mice immunized with either 5 or 15 mg of Hap s . Titers were somewhat lower than those usually observed after parenteral immunization, consistent with immunization by the intranasal route. Titers increased in a dose-dependent manner and were augmented ∼3-fold by the addition of 0.1 mg of CT-E29H. As shown in figure  4 , Western analysis of whole cell sonicates and culture supernatants from strains TN106.P2 and TN106.P2hap with serum from the animals immunized with 15 mg of Hap s plus CT-E29H revealed reactivity virtually exclusively with Hap. Anti-Hap s antibody levels were below the limit of detection in preimmune serum samples and in both mucosal washes and serum samples from control animals that received D-PBS alone or D-PBS with CT-E29H (tables 1 and 2).
Effect of immunization with Hap s on nasopharyngeal colonization. As shown in figure 5, intranasal immunization with native Hap s purified from strain P860295 resulted in a significant reduction in the density of nasal colonization by strain TN106.P2. Comparing control animals administered D-PBS or D-PBS with CT-E29H and those immunized with Hap s , with or without CT-E29H, the reduction in number of organisms recovered per gram of nasal tissue ranged from 1.5 to 2.5 logs when animals were challenged 2 weeks after the last immunization and colonization was measured 3 days after challenge. Colonization was detected in all animals.
Discussion
The H. influenzae Hap protein is a surface-exposed protein that was first discovered on the basis of its ability to promote adherence and low-level invasion in assays with cultured epithelial cells [5] . More recently, we demonstrated that Hap also promotes bacterial aggregation and microcolony formation [4] . Of note, adherence, invasion, and microcolony formation are properties of relevance to colonization, an essential first step in the pathogenesis of H. influenzae disease.
Hap contains an outer membrane domain called Hap b , which is predicted to form a b-barrel with a central pore, and an extracellular domain called Hap s , which is ultimately released from the surface of the cell via an autoproteolytic cleavage event [7] . The Hap s domain has adhesive activity and is responsible for Hap-mediated interaction with host cells and Hap-mediated microcolony formation, while still cell-associated in the fulllength form (before autoproteolysis) [4] .
Given that Hap s is surface-exposed, we reasoned that this domain might be a target for antibodies. Furthermore, since Hap s appears to play a central role in colonization, we reasoned that immunization with Hap s might protect against colonization and thereby prevent disease. In the present study, we used NOTE. Six groups of 10 animals were immunized at weeks 0, 1, 3, and 5, and serum samples were collected at week 7. D-PBS, Dulbecco's PBS. a mouse model of colonization and found that immunization with purified Hap s resulted in a significant reduction in the number of organisms recovered from the nasopharynx 3 days after nasopharyngeal challenge.
In considering a strategy for the development of a vaccine effective against NTHi, it is notable that nontypeable strains display considerable genetic and antigenic heterogeneity. In the present study, we cloned and sequenced the hap genes from 2 epidemiologically distinct strains, designated "P860295" and "TN106." Comparison of the predicted amino-acid sequences from these 2 strains demonstrated ∼80% identity with each other and 77%-83% identity with the prototypic sequence from strain N187. Of importance, we found that immunization of mice with Hap s from strain P860295 stimulated protection against colonization with a heterologous strain, TN106.
It is noteworthy that the addition of CT-E29H to the immunizing preparation augmented the mucosal and serum antibody responses to Hap s . Native CT is well known as a potent mucosal adjuvant but is highly toxic to humans [34] . CT-E29H is a mutant form of CT that contains a histidine in place of a glutamic acid at residue 29 in the enzymatic A subunit. This mutant lacks enzymatic activity and has !1% of the cellular toxicity of native CT but remains fully active as an adjuvant, which suggests considerable use in humans [29] . Of interest, higher titers of antibody were not associated with increased protection in our study, perhaps because even low titers exceeded the relevant threshold in our model.
NTHi causes naturally acquired disease exclusively in humans. As a consequence, efforts thus far to develop an animal model that reproduces all aspects of natural disease have been unsuccessful. The BALB/c challenge model used in our studies is similar to a model described by Hotomii et al. [35] and allows the assessment of colonization, the first step in the pathogenic process. In this model, NTHi strain TN106 consistently colonizes the nasopharynx for up to 5 days after challenge. Thus, in immunized animals, any reduction in colonization at 3 days after challenge probably represents either immune-induced enhanced clearance or inhibition of colonization.
NTHi is a mucosal pathogen and most commonly causes localized respiratory tract disease. With this information in mind, it is possible that vaccines against NTHi will be maximally effective when delivered to the respiratory mucosa. In the present study, we immunized animals via the intranasal route. Significant anti-Hap s titers of both IgA and IgG were observed in BAL fluid and NWs, which suggests a mucosal immune response. In addition, serum titers were elevated, which perhaps reflects the relatively large volume of our immunizing preparation and aspiration of some material into the lungs.
In summary, our results demonstrate that the antibodies elicited by purified Hap s are biologically active against challenge with a heterologous strain of nontypeable H. influenzae. In addition, they indicate that intranasal immunization with Hap s mixed with CT-E29H stimulates an enhanced immune response compared with intranasal immunization with Hap s alone. On the basis of this work, we believe that Hap s has considerable potential as a vaccine against nontypeable H. influenzae.
